ATM activation mediates anticancer immunosurveillance by natural killer and T cells.

abstract：:We have recently described two types of Langerhans cells (LCs), which develop via separate pathways in steady-state conditions and during inflammation. Here, we propose that these two types of LCs differ in their requirement for transforming growth factor β1 (TGFβ1), and we discuss how TGFβ1 impacts on the development...

journal_title：Oncoimmunology

authors： Seré K,Felker P,Hieronymus T,Zenke M

更新日期：2013-03-01 00:00:00

abstract：:Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in tumor rejection without a requirement for T-cell trafficking from lymphatic organs. Rather, IL-10 directly act...

journal_title：Oncoimmunology

authors： Emmerich J,Mumm JB,Oft M

更新日期：2012-12-01 00:00:00

abstract：:Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

journal_title：Oncoimmunology

authors： Tsai AK,Davila E

更新日期：2016-01-15 00:00:00

abstract：:Macrophages promote the growth of leiomyosarcoma (LMS), a malignant soft-tissue tumor. CD47 on tumor cells binds to the macrophagic receptor signal regulatory protein α (SIRPα) and prevents phagocytosis. We showed that anti-CD47 monoclonal antibodies (mAbs) allow macrophages to engulf LMS cells and prevent tumor growt...

journal_title：Oncoimmunology

authors： Edris B,Weiskopf K,Weissman IL,van de Rijn M

更新日期：2012-10-01 00:00:00

abstract：:Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

journal_title：Oncoimmunology

authors： Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

更新日期：2016-05-04 00:00:00

abstract：:Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In order to devise a treatment strategy for patients with glioblastoma...

journal_title：Oncoimmunology

authors： Suryadevara CM,Desai R,Abel ML,Riccione KA,Batich KA,Shen SH,Chongsathidkiet P,Gedeon PC,Elsamadicy AA,Snyder DJ,Herndon JE 2nd,Healy P,Archer GE,Choi BD,Fecci PE,Sampson JH,Sanchez-Perez L

更新日期：2018-02-21 00:00:00

abstract：:Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyz...

journal_title：Oncoimmunology

authors： Kreutzman A,Yadav B,Brummendorf TH,Gjertsen BT,Hee Lee M,Janssen J,Kasanen T,Koskenvesa P,Lotfi K,Markevärn B,Olsson-Strömberg U,Stentoft J,Stenke L,Söderlund S,Udby L,Richter J,Hjorth-Hansen H,Mustjoki S

更新日期：2019-07-13 00:00:00

abstract：:Interleukin-12 immune stimulation lacks efficacy in established solid tumor models. Disruption of tumor microenvironment homeostasis by low-dose cyclophosphamide prior to interleukin-12 gene therapy led to CD8+ T cell-driven established tumor rejection. This only takes place when inflammatory myeloid cells infiltrate ...

journal_title：Oncoimmunology

authors： Medina-Echeverz J,Berraondo P

更新日期：2012-01-01 00:00:00

abstract：:Regressing tumors are usually associated with a large immune infiltrate, but the molecular and cellular interactions that govern a successful anti-tumor immunity remain elusive. Here, we have triggered type I Interferon (IFN) signaling in a breast tumor model (MMTV-PyMT) using 5,6-dimethylxanthenone-4-acetic acid (DMX...

journal_title：Oncoimmunology

authors： Weiss JM,Guérin MV,Regnier F,Renault G,Galy-Fauroux I,Vimeux L,Feuillet V,Peranzoni E,Thoreau M,Trautmann A,Bercovici N

更新日期：2017-07-07 00:00:00

abstract：:Successful cancer immunotherapy necessitates T cell proliferation and infiltration into tumor without exhaustion, a process closely links optimal maturation of dendritic cells (DC), and adjuvant promotes this process as an essential prerequisite. Poly(I:C) has contributed to adjuvant immunotherapy that evokes an antit...

journal_title：Oncoimmunology

authors： Azuma M,Takeda Y,Nakajima H,Sugiyama H,Ebihara T,Oshiumi H,Matsumoto M,Seya T

更新日期：2016-05-19 00:00:00

abstract：:Circulating fibrocytes were reported to represent a novel myeloid-derived suppressor cell (MDSC) subset and they were also proposed to be involved in the tumor immune escape. This novel fibrocyte subset had a surface phenotype resembling non-monocytic MDSCs (CD14-CD11chiCD123-) and exhibited immunomodulatory roles. Mo...

journal_title：Oncoimmunology

authors： Gunaydin G,Kesikli SA,Guc D

更新日期：2015-05-27 00:00:00

abstract：: Background : Peritoneal carcinomatosis (PC) is a terminal evolution from primary colorectal cancer (pCRC) associated with poor patient survival. Impact of the immune cell infiltrate on PC pathogenesis is unknown. Therefore, we characterized the immunological tumor microenv...

journal_title：Oncoimmunology

authors： Seebauer CT,Brunner S,Glockzin G,Piso P,Ruemmele P,Schlitt HJ,Geissler EK,Fichtner-Feigl S,Kesselring R

更新日期：2016-10-14 00:00:00

abstract：:The efficacy of PD-1/PD-L1 blockades is heterogeneous in different molecular subtypes of gastric cancer (GC). In this study, we analyzed relevant clinical trials to identify the molecular subtypes associated with the efficacy of PD-1/PD-L1 blockades, and public datasets, patient samples, and GC cell lines were used fo...

journal_title：Oncoimmunology

authors： Zhao R,Wan Q,Wang Y,Wu Y,Xiao S,Li Q,Shen X,Zhuang W,Zhou Y,Xia L,Song Y,Chen Y,Yang H,Wu X

更新日期：2020-12-30 00:00:00

abstract：:Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR...

journal_title：Oncoimmunology

authors： Mella M,Kauppila JH,Karihtala P,Lehenkari P,Jukkola-Vuorinen A,Soini Y,Auvinen P,Vaarala MH,Ronkainen H,Kauppila S,Haapasaari KM,Vuopala KS,Selander KS

更新日期：2015-05-22 00:00:00

abstract：:Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows p...

journal_title：Oncoimmunology

authors： Chard LS,Lemoine NR,Wang Y

更新日期：2015-07-20 00:00:00

abstract：:The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-...

journal_title：Oncoimmunology

authors： Richardson LG,Nieman LT,Stemmer-Rachamimov AO,Zheng XS,Stafford K,Nagashima H,Miller JJ,Kiyokawa J,Ting DT,Wakimoto H,Cahill DP,Choi BD,Curry WT

更新日期：2020-08-20 00:00:00

abstract：:Granulysin is a protein present in the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, with cytolytic activity against microbes and tumors. Previous work demonstrated the therapeutic effect of intratumoral injection of recombinant granulysin using in vivo models of breast cancer and mult...

journal_title：Oncoimmunology

authors： Ibáñez-Pérez R,Guerrero-Ochoa P,Al-Wasaby S,Navarro R,Tapia-Galisteo A,De Miguel D,Gonzalo O,Conde B,Martínez-Lostao L,Hurtado-Guerrero R,Sanz L,Anel A

更新日期：2019-07-22 00:00:00

abstract：:HSP110 is induced by different stresses and, through its anti-apoptotic and chaperoning properties, helps the cells to survive these adverse situations. In colon cancers, HSP110 is abnormally abundant. We have recently showed that colorectal cancer (CRC) patients with microsatellite instability (MSI) had an improved r...

journal_title：Oncoimmunology

authors： Berthenet K,Boudesco C,Collura A,Svrcek M,Richaud S,Hammann A,Causse S,Yousfi N,Wanherdrick K,Duplomb L,Duval A,Garrido C,Jego G

更新日期：2016-04-22 00:00:00

abstract：:Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor formation in mice and reverse bronchial dysplasia in former smokers. However, the effect of prostacyclin on lung cancer progression has not been well studied. We...

journal_title：Oncoimmunology

authors： Li HY,McSharry M,Walker D,Johnson A,Kwak J,Bullock B,Neuwelt A,Poczobutt JM,Sippel TR,Keith RL,Weiser-Evans MCM,Clambey E,Nemenoff RA

更新日期：2018-02-13 00:00:00

abstract：:Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell surface target to the...

journal_title：Oncoimmunology

authors： Thayaparan T,Petrovic RM,Achkova DY,Zabinski T,Davies DM,Klampatsa A,Parente-Pereira AC,Whilding LM,van der Stegen SJ,Woodman N,Sheaff M,Cochran JR,Spicer JF,Maher J

更新日期：2017-08-14 00:00:00

abstract：:Tumors arise and progress in immunocompetent hosts presumably by activating tolerance mechanisms critical for normal homeostasis. Host immune cells can mount anti-tumor responses by activation of Toll-like receptors (TLRs). However, emerging data suggests that molecules that negatively regulate TLRs are exploited by t...

journal_title：Oncoimmunology

authors： Standiford TJ,Keshamouni VG

更新日期：2012-05-01 00:00:00

abstract：:The optimal sequencing of targeted treatment and immunotherapy in the treatment of advanced melanoma is a key question and prospective studies to address this are ongoing. Previous observations suggest that treating first with targeted therapy may select for more aggressive disease, meaning that patients may not gain ...

journal_title：Oncoimmunology

authors： Simeone E,Grimaldi AM,Festino L,Giannarelli D,Vanella V,Palla M,Curvietto M,Esposito A,Palmieri G,Mozzillo N,Ascierto PA

更新日期：2017-01-19 00:00:00

abstract：:Computerized image analysis for whole-slide images has been shown to improve efficiency, accuracy, and consistency in histopathology evaluations. We aimed to assess whether immunohistochemistry (IHC) image quantitative features can reflect the immune status and provide prognostic information for colorectal cancer pati...

journal_title：Oncoimmunology

authors： Zhao K,Li Z,Li Y,Yao S,Huang Y,Wang Y,Zhang F,Wu L,Chen X,Liang C,Liu Z

更新日期：2020-10-30 00:00:00

abstract：:By merging computational systems modeling and experimental approaches, we have uncovered treatments reprogramming pro-angiogenic monocytes present in breast tumor into immunologically potent cells capable of mediating an anti-tumor immune response. The unraveled pathways and ligands which underlie monocyte pro-angioge...

journal_title：Oncoimmunology

authors： Doucey MA,Xenarios I

更新日期：2015-07-07 00:00:00

abstract：:We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

journal_title：Oncoimmunology

authors： McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

更新日期：2012-07-01 00:00:00

abstract：:Analysis of PDL1 mRNA expression in ∼5,500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with...

journal_title：Oncoimmunology

authors： Bertucci F,Finetti P,Birnbaum D,Mamessier E

更新日期：2015-08-31 00:00:00

abstract：:Immunogenic cell death (ICD) induced by anticancer chemotherapeutics is usually preceded by premortem stress affecting the endoplasmic reticulum (ER). This ER stress does not reflect a canonical unfolded protein response (UPR) but rather manifests solely at the level of the phosphorylation of eIF2α. eIF2α phosphorylat...

journal_title：Oncoimmunology

authors： Bezu L,Sauvat A,Humeau J,Leduc M,Kepp O,Kroemer G

更新日期：2018-02-14 00:00:00

abstract：:Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

journal_title：Oncoimmunology

authors： Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

更新日期：2017-02-21 00:00:00

abstract：:Tumor-associated macrophages (TAM) are well known as a key player in the tumor microenvironment, which support cancer progression. More recently, a lineage of monocytes characterized by the expression of the TIE-2/Tek angiopoietin receptor identified a subset of circulating and tumor-associated monocytes endowed with ...

journal_title：Oncoimmunology

authors： Turrini R,Pabois A,Xenarios I,Coukos G,Delaloye JF,Doucey MA

更新日期：2017-03-16 00:00:00

abstract：:Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer...

journal_title：Oncoimmunology

authors： Park JH,Theodoratou E,Calin GA,Shin JI

更新日期：2016-09-09 00:00:00